Viatris Confirms Delay On ‘First And Only’ Botox Biosimilar

Problems For Partner Revance’s Lead Pipeline Candidate Has ‘Direct Impact’

Viatris remains hopeful of obtaining FDA approval for its proposed biosimilar to Botox in partnership with Revance Therapeutics in 2026, after the latter’s manufacturing problems for another drug candidate stymied development of the rival to the world-renowned cosmetic brand.

Delay Blocks Black White
Both parties commented on the delay to the program • Source: syahrir maulana / Alamy Stock Photo

Viatris’ proposed biosimilar to the world-renowned Botox (onabotulinumtoxinA) cosmetic brand in partnership with Revance Therapeutics will be delayed and the filing pushed back, the firms have announced.

The setback stems from manufacturing concerns for Revance’s lead pipeline candidate, its proposed daxibotulinumtoxinA injectable for the treatment of forehead...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.